Skip to content
type1.science

Beta Bionics iLet Bionic Pancreas

Beta Bionics

An FDA-cleared, insulin-only automated insulin delivery system with a radically simplified control model: no carb counting and no manual basal or correction settings. It is initialized on body weight alone, and the user only announces meals as "usual / more / less."

Available nowRegulator-approvedhybrid-closed-looptubedphone-controlOfficial site ↗

The scorecard

Time in range70

Achieved ~65% time-in-range in the 219-person all-ages (6-79) iLet pivotal RCT (NEJM 2022), using the achieved level not the +11-point delta; an adult-only Fiasp arm reached 71% but real-world commercial GMI (7.2% adults / 7.7% children, n=6,992) implies only low-60s% TIR, so it sits below the 780G anchor.[10]

Hypo protection78

Achieved just 1.8% time-below-70 and 0.3% time-below-54 in the 219-person all-ages pivotal RCT, with the same 0.3% time-below-54 confirmed in 6,992 real-world T1D users — a strong, low-hypoglycemia profile for a meal-announcement-light loop.[10]

Automation level82

Class-leading ease — no carb counting, no manual basal/correction; auto-corrections plus relative meal announcements only.[2]

Average glucose70

Achieved HbA1c 7.3% (mean glucose 164 mg/dL) in the all-ages pivotal RCT; real-world iLet GMI was 7.2% in 5,987 adults and 7.7% in 1,005 children, tracking the time-in-range score.[10]

Low variability70

Achieved coefficient of variation ~33% in the 111-adult Fiasp iLet arm (within the <36% target); robust glucose SD reductions vs standard care, though CV is reported mainly in the adult cohort.[11]

Exercise handling50

No exercise mode or temporary target; users disconnect or eat to manage activity — a notable gap.[5]

Customizability35

By design there are almost no adjustable settings — its strength for simplicity, its weakness for power users.[2]

Access & cost58

US-only, on prescription; works with Dexcom G6/G7 and FreeStyle Libre 3 Plus.[8]

Freedom (form factor)48

A tubed pump with a simple interface — standard tubed form factor with a clip-on body and infusion line.

Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.

Editor’s take

The iLet bets everything on one idea: that the safest dose is the one nobody has to calculate. Strip out carb counting, basal rates, and correction factors, and you remove the biggest sources of human error — at the cost of the fine control some users want. Its trial gains are solid rather than spectacular, but its real contribution is lowering the barrier to automation. The missing exercise mode and the lack of tunable targets are the clear next problems to solve; the bihormonal (insulin + glucagon) version aims at the rest. Beta Bionics has also done something no rival has: since June 2026 it publishes its real-world outcomes on a public dashboard, with no cherry-picked cohort. That transparency deserves credit — but note the headline figures are improvements from a high-HbA1c starting population, not the level users end up at, so they do not by themselves move our scores.

The full picture

The Beta Bionics iLet Bionic Pancreas is an automated insulin delivery (AID) system built around a deliberately radical idea: take the math away from the user. It pairs the iLet ACE tubed insulin pump, the iLet Dosing Decision Software algorithm, and a compatible continuous glucose monitor (CGM) that streams glucose readings to the pump.1 The FDA cleared it for people aged 6 and older with type 1 diabetes in May 2023.1

What sets it apart is initialization and operation. Where other systems need basal rates, carb ratios, and correction factors, the iLet is set up using only the user's body weight and then learns from there.2 There is no carb counting and no manual basal or correction dosing. The algorithm independently decides whether to raise, lower, hold, or suspend basal insulin and issues correction doses automatically.1 At meals, the user simply announces breakfast, lunch, or dinner and picks a relative size — "usual for me," "more," or "less" — and the system handles the dose.3 This makes it the most automated AID system to set up, though it remains a hybrid loop: meals still have to be announced.3

In the pivotal 13-week multicenter randomized trial (326 participants aged 6–79; insulin-only configuration), HbA1c fell from 7.9% to 7.3% on the bionic pancreas versus no change (7.7%) on standard care — an adjusted difference of −0.5 percentage points.4 Time in range (70–180 mg/dL) rose by about 11% (roughly 2.6 hours/day) and mean CGM glucose dropped about 16 mg/dL.4 Crucially, time below 54 mg/dL was statistically noninferior to standard care, and no diabetic ketoacidosis occurred; severe-hypoglycemia rates did not differ significantly between groups.4 Benefits appeared within the first day and held steady through 13 weeks, and the youth (6–17) cohort and a cystic-fibrosis-related-diabetes trial showed comparable gains.56

Automation level: the iLet auto-titrates basal continuously and delivers automatic correction doses; the only routine user action is the relative meal announcement, with no carb counting.13 Exercise handling is its weakest area — there is no exercise mode and no temporary glucose target, so users manage activity by disconnecting the pump or eating extra carbs.7 Customizability is intentionally minimal: the trade for simplicity is that there are essentially no targets or rates to tune.2

Ages and indications: cleared for type 1 diabetes from age 6 upward in the United States.1 Access: available on prescription in the US only. It launched working with the Dexcom G6, added Dexcom G7, and in October 2024 became the first US AID system to integrate Abbott's FreeStyle Libre 3 Plus sensor.8

An unusual amount of transparency

In June 2026 Beta Bionics became the first AID manufacturer to publish near-real-time real-world outcomes on a public website.9 The dashboard covers every iLet user who has a provider-reported baseline HbA1c and at least two weeks of uploaded CGM data — the company states there are no other exclusions, so it is not a hand-picked cohort. Trade-press coverage of the launch reported a roughly 25% improvement in time in range.10 The same piece quotes one clinician saying that 73% of his own iLet patients reached a glucose management indicator (GMI) of 7.5% or below, against 20% before iLet — but that is one clinic's caseload, not a figure from the dashboard, and should not be read as a population result.10

Read those figures carefully. They are improvements measured from a starting population with high HbA1c, not the level users actually land at — a group that starts badly controlled can post a huge improvement and still end up in the same place as everyone else. That is why we have not moved the time-in-range or average-glucose scores on this page: those scores track achieved levels, and the best evidence for iLet's achieved levels is still the pivotal trial and the published real-world GMI data.4 The transparency itself is genuinely unusual and worth crediting; it just is not the same thing as a better outcome.

What's coming: Beta Bionics' headline next step is a bihormonal (dual-hormone) version of the iLet that adds dasiglucagon — a chemically stable glucagon analog — so the system can dose a counter-regulatory hormone to defend against lows, not just reduce insulin. In an adult home-use study the bihormonal iLet delivered dasiglucagon reliably and kept time below 54 mg/dL (3.0 mmol/L) under 1%, supporting its move into larger phase 2/3 trials.11 If it reaches market, that would push the iLet closer to a true closed loop by attacking the hypoglycemia and exercise gaps that the insulin-only system still leaves to the user.

The other thing in the pipeline is form factor. Beta Bionics is developing Mint, a tubeless patch pump that runs the same iLet algorithm — which would remove the tubing that is the iLet's main lifestyle drawback today. The company has said it is targeting full commercialization by the end of Q2 2027, subject to FDA clearance of the pump's 510(k).12 That is company guidance for a device that is not yet cleared, so treat the date as a plan, not a promise.

References

  1. FDA. FDA Clears New Insulin Pump and Algorithm-Based Software to Support Enhanced Automatic Insulin Delivery (2023). https://www.fda.gov/news-events/press-announcements/fda-clears-new-insulin-pump-and-algorithm-based-software-support-enhanced-automatic-insulin-delivery ↩ ↩2 ↩3 ↩4 ↩5

  2. FDA. 510(k) Clearance Letter K223846 — iLet ACE Pump / iLet Dosing Decision Software (2023). https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223846.pdf ↩ ↩2

  3. Beta Bionics. Meal Announcements Guide for the iLet Bionic Pancreas. https://www.betabionics.com/articles/meal-announcements/ ↩ ↩2 ↩3

  4. Bionic Pancreas Research Group. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med (2022). https://pubmed.ncbi.nlm.nih.gov/36170500/ ↩ ↩2 ↩3 ↩4

  5. Messer LH, et al. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6–17 Years Old with Type 1 Diabetes. Diabetes Technol Ther (2022). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529304/ ↩

  6. Sherwood JS, et al. Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis–Related Diabetes. Diabetes Care (2024). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10733649/ ↩

  7. Beta Bionics. iLet Bionic Pancreas System User Educational Resource Guide (LA000061_G). https://www.betabionics.com/wp-content/uploads/LA000061_G-Educational-Resource-Guide.pdf ↩

  8. Beta Bionics. Partnership to Integrate the iLet Bionic Pancreas with FreeStyle Libre 3 Plus iCGM (2024). https://www.newswire.com/news/beta-bionics-announces-partnership-with-abbott-to-integrate-the-ilet-22413265 ↩

  9. Beta Bionics. Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website (2 June 2026). https://www.globenewswire.com/news-release/2026/06/02/3305268/0/en/beta-bionics-first-in-automated-insulin-delivery-to-publish-near-real-time-real-world-data-on-a-public-website.html ↩

  10. Drug Delivery Business. Beta Bionics real-world data shows 25% time in range improvement with iLet (10 June 2026). https://www.drugdeliverybusiness.com/beta-bionics-real-world-data-shows-25-time-in-range-improvement-with-ilet/ ↩ ↩2

  11. Castellanos LE, et al. Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting. Diabetes Care (2021). https://pmc.ncbi.nlm.nih.gov/articles/PMC8247518/ ↩

  12. Closed-Loop Updates from ADA 2026 — iLet real-world data and the Mint patch pump. https://www.diabetotech.com/blog/closed-loop-updates-from-ada-2026 (conference recap, not a primary source) ↩

What's next for this

  • →Bihormonal (dual-hormone) version of the iLet adding dasiglucagon (stable glucagon analog) to defend against lows; moving into larger phase 2/3 trials
  • →Mint tubeless patch pump running the iLet algorithm — full commercialization · Targeted by end of Q2 2027, subject to FDA clearance of the ACE pump 510(k)

Sources

  1. [1]Bionic Pancreas Research Group. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med (2022). · peer-reviewed — Pivotal RCT, n=326 (219 BP / 107 SC), ages 6–79, NCT04200313. DOI 10.1056/NEJMoa2205225.
  2. [2]FDA. FDA Clears New Insulin Pump and Algorithm-Based Software to Support Enhanced Automatic Insulin Delivery (2023). · regulatory — 510(k) clearance of iLet ACE Pump + iLet Dosing Decision Software, ages 6+, body-weight initialization, no carb counting.
  3. [3]FDA. 510(k) Clearance Letter K223846 — iLet ACE Pump / iLet Dosing Decision Software (2023). · regulatory
  4. [4]Beta Bionics. Meal Announcements Guide for the iLet Bionic Pancreas. · manufacturer
  5. [5]Beta Bionics. iLet Bionic Pancreas System User Educational Resource Guide (LA000061_G). · manufacturer
  6. [6]Messer LH, et al. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6–17 Years Old. Diabetes Technol Ther (2022). · peer-reviewed
  7. [7]Sherwood JS, et al. Randomized Trial of the Insulin-Only iLet Bionic Pancreas for Cystic Fibrosis–Related Diabetes. Diabetes Care (2024). · peer-reviewed
  8. [8]Beta Bionics. Partnership to Integrate the iLet Bionic Pancreas with FreeStyle Libre 3 Plus iCGM (2024). · manufacturer
  9. [9]Castellanos LE, et al. Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting. Diabetes Care (2021). · peer-reviewed
  10. [10]Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes · peer-reviewed · 2022-09-29
  11. [11]A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes · peer-reviewed · 2022-10-01
  12. [12]129-OR: Real-World Efficacy of the iLet Bionic Pancreas in Adults and Children during the First Eighteen Months of Commercial Availability · conference · 2025-06-20
  13. [13]Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website · manufacturer · 2026-06-02 — Company announcement. The dashboard covers 100% of iLet users who have a provider-reported baseline HbA1c and at least two weeks of uploaded CGM data, with no other exclusions. The press release itself contains no outcome numbers — those live on the dashboard.
  14. [14]Beta Bionics real-world data shows 25% time in range improvement with iLet · news · 2026-06-10 — Trade-press write-up of the dashboard. Figures reported are improvements from baseline, not achieved levels.
  15. [15]Closed-Loop Updates from ADA 2026 — iLet real-world data and the Mint patch pump · community — Conference recap, not a primary source. Cited here only for Beta Bionics' stated Mint commercialization timing.